Press releases

25 Oct 2025

BIMZELX[®] (bimekizumab-bkzx) three year rheumatology data at ACR 2025 demonstrated sustained inflammation control in psoriatic arthritis and axial spondyloarthritis

14 Oct 2025

Final analysis of open-label extension (OLE) study of Fintepla[®]▼ (fenfluramine) in Lennox-Gastaut syndrome published in Epilepsy and Behavior

13 Oct 2025

Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)

9 Oct 2025

Transparency notification FMR LLC

18 Sep 2025

UCB announces successful first-in-patient trial for galvokimig in moderate-to-severe atopic dermatitis at EADV

17 Sep 2025

BIMZELX[®]▼(bimekizumab) new three-year data in hidradenitis suppurativa at EADV showed sustained disease control across the most stringent clinical endpoints

Press releases

Press releases

Search Press releases

BIMZELX[®] (bimekizumab-bkzx) three year rheumatology data at ACR 2025 demonstrated sustained inflammation control in psoriatic arthritis and axial spondyloarthritis

Final analysis of open-label extension (OLE) study of Fintepla[®]▼ (fenfluramine) in Lennox-Gastaut syndrome published in Epilepsy and Behavior

Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)

Transparency notification FMR LLC

UCB announces successful first-in-patient trial for galvokimig in moderate-to-severe atopic dermatitis at EADV

BIMZELX[®]▼(bimekizumab) new three-year data in hidradenitis suppurativa at EADV showed sustained disease control across the most stringent clinical endpoints

Choose a Country

Hypothesize That! Discover our new science podcast, where science meets conjecture and curiosity

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

At UCB, we imagine an HS-free world. And we’re taking steps to make it a reality. Download our...

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2024 - Click here to access the report

UCBCares® - Discover what UCBCares® is about and the services they offer

Driving innovation forward: UCB unveils new R&D facility

Final analysis of open-label extension (OLE) study of Fintepla[®]▼ (fenfluramine) in Lennox-Gastaut...

From Differentiated Innovation to Outstanding Delivery - A Strong First Half Performance

UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity

From Differentiated Innovation to Outstanding Delivery - A Strong First Half Performance

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

BIMZELX[®] (bimekizumab-bkzx) three year rheumatology data at ACR 2025 demonstrated sustained inflammation control in psoriatic arthritis and axial spondyloarthritis

Final analysis of open-label extension (OLE) study of Fintepla[®]▼ (fenfluramine) in Lennox-Gastaut syndrome published in Epilepsy and Behavior

Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)

Transparency notification FMR LLC

UCB announces successful first-in-patient trial for galvokimig in moderate-to-severe atopic dermatitis at EADV

BIMZELX[®]▼(bimekizumab) new three-year data in hidradenitis suppurativa at EADV showed sustained disease control across the most stringent clinical endpoints

Choose a Country